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background: The DANPACE study (EHJ 2013;15:1166-73) suggested implanting DDDR pacemakers in pts with sick sinus syndrome (SSS) even in 
the absence of atrioventricular block (AVB), although 91.7% of their AAIR group did not require upgrade. Moreover, complications from implanting 
2 leads and tricuspid regurgitation incidence were not reported. AAIR pacing offers many advantages: decreased cost/complications with 1 lead; 
no tricuspid regurgitation; less ventricular dyssynchrony. Nevertheless, most centres implant DDDR pacemakers due to the worry of future AVB. The 
present study looks at the long term outcome of AAIR implants at a single centre.
methods: Pts presenting from 1990-2012 with SSS without AVB (no LBBB, bifascicular block, or PR > 220 ms), had AAIR pacemakers implanted. At 
implant, atrial pacing was performed; ventricular leads were implanted for a Wenckebach rate < 120 bpm.
results: 87 pts (41.4% male; mean age 69.7 ± 1.4 SEM yrs) received AAIR pacemakers. Two pts were lost to follow-up after 1.3 ± 0.0 yrs with no 
incidents recorded. Of the remaining 85 pts, 78 (91.8%) did not require an upgrade (mean follow-up 10.6 ± 0.6 yrs). Amongst this group, 31 pts 
(39.7%) were alive (mean follow-up 14.3 ± 0.7 yrs) while 47 (60.3%) were deceased (mean follow-up 8.1 ± 0.7 yrs) at the end of June 2013. The 
causes of death were: 29 (61.7%) from old age (mean age 86.6 ± 1.4 yrs); 6 (12.8%) cancer; 4 (8.5%) pneumonia; 2 (4.3%) renal failure; 2 (4.3%) 
myocardial infarction; 2 (4.3%) stroke; 1 (2.1%) GI bleed; 1 (2.1%) urosepsis. There were no sudden deaths attributable to AVB. During the study, 
7 pts (8.2%) received a new ventricular lead: 2 presented with symptomatic AVB (at 1.8, 2.3 yrs); 1 had recurrent atrial fibrillation requiring beta-
blockade (at 18.3 yrs); 1 had recurrent atrial lead dislodgment (at 0.2 yrs); 3 were electively upgraded at battery end-of-life for Wenckebach rates 
below 120 bpm at replacement (at 1.8, 3.3, 13.5 yrs).
conclusions: This study confirms the safety of AAIR pacemakers with only 2.3% of pts developing AVB requiring urgent upgrade (mean follow-up 
10.6 yrs versus 5.4 yrs in DANPACE). Considering the advantages of AAIR pacemakers, this mode of pacing can be selected for pts with SSS without 
AVB.
